MedTrace Logo

A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors

NCT05528055 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2022-09-06

No results posted yet for this study

Summary

A Phase 1, open label, multi center, dose escalation and expansion study will assess the safety, tolerability, PK, and preliminary efficacy of SCR-6920 capsule in participants with advanced malignant tumors. The purpose of the study is to identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D), and to confirm the tolerability and preliminary efficacy of SCR-6920 in participants with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma(NHL).

Conditions

Interventions

DRUG

SCR-6920 capsule

SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis

DRUG

SCR-6920 capsule

SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis

DRUG

SCR-6920 capsule

SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis

DRUG

SCR-6920 capsule

SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis

Sponsors & Collaborators

  • Jiangsu Simcere Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-18
Primary Completion
2027-10-31
Completion
2027-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05528055 on ClinicalTrials.gov